Clinical management of COVID-19.
Identifieur interne : 001255 ( Main/Corpus ); précédent : 001254; suivant : 001256Clinical management of COVID-19.
Auteurs : George M. Varghese ; Rebecca John ; Abi Manesh ; Rajiv Karthik ; O C AbrahamSource :
- The Indian journal of medical research [ 0971-5916 ] ; 2020.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Adrenal Cortex Hormones (therapeutic use), Airway Management (MeSH), Alanine (analogs & derivatives), Alanine (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (therapy), Critical Illness (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunization, Passive (MeSH), Pandemics (MeSH), Patient Acuity (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (therapy), SARS-CoV-2 (MeSH), Shock (therapy), Specimen Handling (MeSH), Symptom Assessment (MeSH), Vulnerable Populations (MeSH).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Adrenal Cortex Hormones, Alanine, Antibodies, Monoclonal, Humanized, Antimalarials, Antiviral Agents, Hydroxychloroquine.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- therapy : Coronavirus Infections, Pneumonia, Viral, Shock.
- Airway Management, Betacoronavirus, COVID-19, Critical Illness, Humans, Immunization, Passive, Pandemics, Patient Acuity, SARS-CoV-2, Specimen Handling, Symptom Assessment, Vulnerable Populations.
Abstract
The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic. Maximal precautionary measures and resources have been put forward by most nations in war footing to mitigate transmission and decrease fatality rates. This article was aimed to review the evidence on clinical management and to deal with the identification of high-risk groups, warning signs, appropriate investigations, proper sample collection for confirmation, general and specific treatment measures, strategies as well as infection control in the healthcare settings. Advanced age, cardiovascular disease, diabetes, hypertension and cancer have been found to be the risk factors for severe disease. Fever lasting for >five days with tachypnoea, tachycardia or hypotension are indications for urgent attention and hospitalization in a patient with suspected COVID-19. At present, reverse transcription-polymerase chain reaction (RT-PCR) from the upper respiratory tract samples is the diagnostic test of choice. While many drugs have shown in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are insufficient clinical data to promote or dissuade their usage. Among the currently available drugs, hydroxychloroquine and lopinavir/ritonavir may be considered for patients with severe COVID-19 infection, awaiting further clinical trials. Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19.
DOI: 10.4103/ijmr.IJMR_957_20
PubMed: 32611911
PubMed Central: PMC7530435
Links to Exploration step
pubmed:32611911Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical management of COVID-19.</title><author><name sortKey="Varghese, George M" sort="Varghese, George M" uniqKey="Varghese G" first="George M" last="Varghese">George M. Varghese</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author><author><name sortKey="John, Rebecca" sort="John, Rebecca" uniqKey="John R" first="Rebecca" last="John">Rebecca John</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author><author><name sortKey="Manesh, Abi" sort="Manesh, Abi" uniqKey="Manesh A" first="Abi" last="Manesh">Abi Manesh</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author><author><name sortKey="Karthik, Rajiv" sort="Karthik, Rajiv" uniqKey="Karthik R" first="Rajiv" last="Karthik">Rajiv Karthik</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author><author><name sortKey="Abraham, O C" sort="Abraham, O C" uniqKey="Abraham O" first="O C" last="Abraham">O C Abraham</name><affiliation><nlm:affiliation>Department of General Medicine & Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32611911</idno><idno type="pmid">32611911</idno><idno type="doi">10.4103/ijmr.IJMR_957_20</idno><idno type="pmc">PMC7530435</idno><idno type="wicri:Area/Main/Corpus">001255</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001255</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical management of COVID-19.</title><author><name sortKey="Varghese, George M" sort="Varghese, George M" uniqKey="Varghese G" first="George M" last="Varghese">George M. Varghese</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author><author><name sortKey="John, Rebecca" sort="John, Rebecca" uniqKey="John R" first="Rebecca" last="John">Rebecca John</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author><author><name sortKey="Manesh, Abi" sort="Manesh, Abi" uniqKey="Manesh A" first="Abi" last="Manesh">Abi Manesh</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author><author><name sortKey="Karthik, Rajiv" sort="Karthik, Rajiv" uniqKey="Karthik R" first="Rajiv" last="Karthik">Rajiv Karthik</name><affiliation><nlm:affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author><author><name sortKey="Abraham, O C" sort="Abraham, O C" uniqKey="Abraham O" first="O C" last="Abraham">O C Abraham</name><affiliation><nlm:affiliation>Department of General Medicine & Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Indian journal of medical research</title><idno type="ISSN">0971-5916</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Airway Management (MeSH)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antimalarials (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (therapy)</term><term>Critical Illness (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunization, Passive (MeSH)</term><term>Pandemics (MeSH)</term><term>Patient Acuity (MeSH)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (therapy)</term><term>SARS-CoV-2 (MeSH)</term><term>Shock (therapy)</term><term>Specimen Handling (MeSH)</term><term>Symptom Assessment (MeSH)</term><term>Vulnerable Populations (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Adrenal Cortex Hormones</term><term>Alanine</term><term>Antibodies, Monoclonal, Humanized</term><term>Antimalarials</term><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Shock</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Airway Management</term><term>Betacoronavirus</term><term>COVID-19</term><term>Critical Illness</term><term>Humans</term><term>Immunization, Passive</term><term>Pandemics</term><term>Patient Acuity</term><term>SARS-CoV-2</term><term>Specimen Handling</term><term>Symptom Assessment</term><term>Vulnerable Populations</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic. Maximal precautionary measures and resources have been put forward by most nations in war footing to mitigate transmission and decrease fatality rates. This article was aimed to review the evidence on clinical management and to deal with the identification of high-risk groups, warning signs, appropriate investigations, proper sample collection for confirmation, general and specific treatment measures, strategies as well as infection control in the healthcare settings. Advanced age, cardiovascular disease, diabetes, hypertension and cancer have been found to be the risk factors for severe disease. Fever lasting for >five days with tachypnoea, tachycardia or hypotension are indications for urgent attention and hospitalization in a patient with suspected COVID-19. At present, reverse transcription-polymerase chain reaction (RT-PCR) from the upper respiratory tract samples is the diagnostic test of choice. While many drugs have shown in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are insufficient clinical data to promote or dissuade their usage. Among the currently available drugs, hydroxychloroquine and lopinavir/ritonavir may be considered for patients with severe COVID-19 infection, awaiting further clinical trials. Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32611911</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0971-5916</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>The Indian journal of medical research</Title><ISOAbbreviation>Indian J Med Res</ISOAbbreviation></Journal><ArticleTitle>Clinical management of COVID-19.</ArticleTitle><Pagination><MedlinePgn>401-410</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijmr.IJMR_957_20</ELocationID><Abstract><AbstractText>The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic. Maximal precautionary measures and resources have been put forward by most nations in war footing to mitigate transmission and decrease fatality rates. This article was aimed to review the evidence on clinical management and to deal with the identification of high-risk groups, warning signs, appropriate investigations, proper sample collection for confirmation, general and specific treatment measures, strategies as well as infection control in the healthcare settings. Advanced age, cardiovascular disease, diabetes, hypertension and cancer have been found to be the risk factors for severe disease. Fever lasting for >five days with tachypnoea, tachycardia or hypotension are indications for urgent attention and hospitalization in a patient with suspected COVID-19. At present, reverse transcription-polymerase chain reaction (RT-PCR) from the upper respiratory tract samples is the diagnostic test of choice. While many drugs have shown in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are insufficient clinical data to promote or dissuade their usage. Among the currently available drugs, hydroxychloroquine and lopinavir/ritonavir may be considered for patients with severe COVID-19 infection, awaiting further clinical trials. Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varghese</LastName><ForeName>George M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manesh</LastName><ForeName>Abi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karthik</LastName><ForeName>Rajiv</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>O C</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>Department of General Medicine & Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Med Res</MedlineTA><NlmUniqueID>0374701</NlmUniqueID><ISSNLinking>0971-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Indian J Med Res. 2020 Jul & Aug;152(1 & 2):149-151</RefSource><PMID Version="1">32883919</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Indian J Med Res. 2020 Jul & Aug;152(1 & 2):151-152</RefSource><PMID Version="1">32883920</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058109" MajorTopicYN="N">Airway Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062072" MajorTopicYN="N">Patient Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013048" MajorTopicYN="N">Specimen Handling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035862" MajorTopicYN="N">Vulnerable Populations</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical management - corticosteroids - COVID-19 - hydroxychloroquine - lopinavir - remdesivir - risk groups - SARS-CoV-2</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32611911</ArticleId><ArticleId IdType="pii">IndianJMedRes_2020_151_5_401_285357</ArticleId><ArticleId IdType="doi">10.4103/ijmr.IJMR_957_20</ArticleId><ArticleId IdType="pmc">PMC7530435</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation><ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Jul 1;5(7):751-753</Citation><ArticleIdList><ArticleId IdType="pubmed">32219362</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2020 Jul 23;58(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">32366669</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975</Citation><ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation><ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation><ArticleIdList><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2004 Dec;31(4):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15494274</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2020 May 1;130(5):2620-2629</Citation><ArticleIdList><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation><ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105954</Citation><ArticleIdList><ArticleId IdType="pubmed">32234467</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):854-887</Citation><ArticleIdList><ArticleId IdType="pubmed">32222812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mil Med Res. 2020 Mar 13;7(1):11</Citation><ArticleIdList><ArticleId IdType="pubmed">32169119</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2020 Jun 16;141(24):e906-e907</Citation><ArticleIdList><ArticleId IdType="pubmed">32267732</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2020 Jan;25(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134</Citation><ArticleIdList><ArticleId IdType="pubmed">32119647</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 21;395(10228):931-934</Citation><ArticleIdList><ArticleId IdType="pubmed">32164834</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):583-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16172857</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):327-47</Citation><ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation><ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 28;323(16):1582-1589</Citation><ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101623</Citation><ArticleIdList><ArticleId IdType="pubmed">32179124</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation><ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):425-434</Citation><ArticleIdList><ArticleId IdType="pubmed">32105637</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):846-848</Citation><ArticleIdList><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2016 Jan 7;374(1):33-42</Citation><ArticleIdList><ArticleId IdType="pubmed">26735992</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Jul 1;5(7):802-810</Citation><ArticleIdList><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Mar 19;382(12):1177-1179</Citation><ArticleIdList><ArticleId IdType="pubmed">32074444</ArticleId></ArticleIdList></Reference><Reference><Citation>Engineering (Beijing). 2020 Mar 18;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32346491</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2020 Jun 1;201(11):1337-1344</Citation><ArticleIdList><ArticleId IdType="pubmed">32298146</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(4):e35797</Citation><ArticleIdList><ArticleId IdType="pubmed">22563403</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiology. 2020 Aug;296(2):E32-E40</Citation><ArticleIdList><ArticleId IdType="pubmed">32101510</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation><ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 16;382(16):1564-1567</Citation><ArticleIdList><ArticleId IdType="pubmed">32182409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation><ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 20;43(0):E019</Citation><ArticleIdList><ArticleId IdType="pubmed">32075365</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101615</Citation><ArticleIdList><ArticleId IdType="pubmed">32145386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation><ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Infection. 2020 Oct;48(5):773-777</Citation><ArticleIdList><ArticleId IdType="pubmed">32277408</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation><ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tob Induc Dis. 2020 Mar 20;18:20</Citation><ArticleIdList><ArticleId IdType="pubmed">32206052</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767</Citation><ArticleIdList><ArticleId IdType="pubmed">29161116</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Med. 2019 Jun 03;8(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">31163625</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 23;382(17):1653-1659</Citation><ArticleIdList><ArticleId IdType="pubmed">32227760</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001255 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001255 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32611911
|texte= Clinical management of COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32611911" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |